NCT02231671View on ClinicalTrials.gov

A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

November 30, 2014

Conditions
Respiratory Syncytial Virus Infections
Interventions
DRUG

ALS-008176

DRUG

ALS-008112

Trial Locations (1)

NG11 6JS

Quotient Clinical, Nottingham

Sponsors
All Listed Sponsors
lead

Alios Biopharma Inc.

INDUSTRY

NCT02231671 - A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176 | Biotech Hunter | Biotech Hunter